Hereditary alpha-tryptasemia modifies GI disease outcomes in individuals of European ancestry.

This systematic review evaluated the role of Hereditary alpha-tryptasemia (HαT), defined by an increased TPSAB1 copy number, as a modifier of gastrointestinal (GI) disease in individuals of European ancestry. The review focused on conditions including celiac disease and inflammatory bowel disease (IBD), comparing outcomes in those with HαT against individuals without the trait or without overt GI pathology. Specific study designs, sample sizes, and settings were not reported in the available evidence.

The primary findings indicate that the HαT trait is present in approximately 4%–6% of individuals of European ancestry. Among those who test positive for the genetic trait, core clinical features manifest in one-third of cases. In the context of celiac disease, the presence of HαT is associated with increased duodenal mast cells and persistent GI symptoms, such as diarrhea, bloating, and abdominal pain, despite adherence to a gluten-free diet.

Regarding inflammatory bowel disease, increased alpha-tryptase gene dosage is associated with intestinal mast cell activation and increased expression of MRGPRX2. These associations suggest a mechanistic link between the genetic trait and disease severity or persistence. However, the review did not report specific adverse events, discontinuations, or tolerability data, nor did it provide p-values or confidence intervals for the reported associations.

Key limitations include the lack of reported sample sizes and study designs, which prevents a rigorous assessment of statistical certainty. The review concludes that HαT is a clinically significant modifier of disease in the GI tract. Clinicians should interpret these findings as observational associations rather than definitive causal relationships, particularly given the absence of reported causality notes or certainty assessments in the source material.